Xiidra®
Lifitegrast is a small molecule integrin antagonist for the treatment of dry eye disease. It blocks T-cell mediated inflammation on the ocular surface.
| Dosage Form | Ophthalmic Solution (Single-Use Containers) |
| Strength | 5% (50 mg/mL) |
| Storage | Store at 20–25°C. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Dry eye disease (signs and symptoms).
Blocks the interaction between lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1), inhibiting T-cell recruitment, activation, and cytokine release.
Each Burrard Pharmaceuticals technology transfer package for Lifitegrast includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.